phrykt

IGC Pharma, Inc. (IGC): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of IGC were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No IGC insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IGC short interest

Low short interest. 0.4% of IGC shares are sold short: about 1 share in 261. Over the last 12 reports the number of shares short went down 69%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 395,551 IGC shares were sold short, 0.4% of the shares outstanding, down 37.8% from the report before. At the average daily volume of 508,862 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.38%May 15Oct 301.48%

Days to cover

1.0May 15Oct 303.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026395,5510.38%-38%508,8621.0
Oct 15, 2026635,6400.61%-32%715,2071.0
Sep 30, 2026931,5120.90%-13%648,2701.4
Sep 15, 20261.07M1.04%+48%524,3872.0
Aug 31, 2026724,8440.70%-6%1.09M1.0
Aug 14, 2026767,6480.74%+42%1.04M1.0
Jul 31, 2026541,6990.55%+39%322,9411.7
Jul 15, 2026389,0570.39%-20%437,8521.0
Jun 30, 2026484,8120.49%+133%591,8061.0
Jun 15, 2026208,1030.21%-82%676,7311.0
May 29, 20261.18M1.19%-9%871,4641.4
May 15, 20261.30M1.31%+12%470,7112.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

IGC Pharma company events

IGC Pharma filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Jul 14, 2026.

  1. Jul 14, 2026AnnouncementShared information with investors. Filing
  2. Jul 6, 2026AgreementIGC Pharma, Inc. entered into separate Stock Purchase Agreements with Ram Mukunda, the Company’s Chief Executive Officer, and Claudia Grimaldi, the Company’s Vice President and Principal Financial Officer, pursuant to which Mr. Mukunda and Ms. Grimaldi purchased shares of the Company’s common… Filing
  3. Jun 8, 2026AgreementIGC Pharma, Inc. entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as lender. Filing
  4. Apr 20, 2026AgreementIGC Pharma, Inc. executed a Securities Purchase Agreement with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company. Filing
  5. Mar 30, 2026AnnouncementIGC Pharma, Inc. issued a press release announcing a strategic national media partnership with FMW Media Works LLC (New to The Street), a financial media platform, as part of the Company’s investor relations and corporate communications initiatives. Filing
  6. Mar 12, 2026AgreementIGC Pharma, Inc. entered into a Securities Purchase Agreement with Vanquish Funding Group Inc., a Virginia corporation. Filing
  7. Jan 6, 2026AgreementIGC Pharma, Inc. entered into a Subscription Agreement with certain investors named therein, pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering, an aggregate of 779,997 shares of the Company’s common stock, par value $0.0001 per share, at a… Filing
  8. Jan 2, 2026RulesChanged its bylaws or articles. Filing
  9. Dec 15, 2025RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Famous investors that hold IGC

3 of the 50 well-known investors we track reported holding IGC in their latest 13F filing. The largest position is Ken Griffin's, worth $198K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026735,693$198K0.0%+68%
Jim Simons · Renaissance TechnologiesQ3 2026653,458$176K0.0%+128%
Ken Fisher · Fisher Asset ManagementQ3 202643,400$11.7K0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about IGC Pharma, Inc. (IGC) stock

Are IGC insiders buying or selling?

No IGC insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in IGC?

As of Oct 30, 2026, 395,551 IGC shares were sold short, 0.4% of the shares outstanding, down 37.8% from the report before. At the average daily volume of 508,862 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold IGC?

3 of the 50 well-known investors we track reported IGC in their latest 13F filing, including Ken Griffin, Jim Simons, Ken Fisher. The largest position is worth $198K. See all holders.

Executive pay

IGC Pharma's chief executive was paid a total of $568K for the year ended Mar 31, 2025, down 69% from $1.8M the year before. In the last 12 months, IGC Pharma's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$568KYear ended Mar 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$259KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.